175838-22-9

Basic information

• Product Name: N,3-dihydroxybenzenecarboximidamide
• CAS NO: 175838-22-9
• Molecular Formula: C₇H₈N₂O₂
• Molecular Weight: 152.1506
• Mol File: 175838-22-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 335.522°C at 760 mmHg
• Flash Point: 156.719°C
• Density: 1.35g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.607
• CAS DataBase Reference: N,3-dihydroxybenzenecarboximidamide(CAS DataBase Reference)
• NIST Chemistry Reference: N,3-dihydroxybenzenecarboximidamide(175838-22-9)
• EPA Substance Registry System: N,3-dihydroxybenzenecarboximidamide(175838-22-9)

Safety Data

• Hazardous Substances Data: 175838-22-9(Hazardous Substances Data)

Upstream product

• 873-62-1 m-cyanophenol 
• 99-06-9 3-Carboxyphenol 
• 40812-76-8 3-hydroxybenzoyl chloride 
• 618-49-5 3-hydroxybenzamide 

Downstream Products

• 1258010-53-5 3-(5-(1-cyclohexyl-5-(methoxymethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenol 
• 1363593-63-8 3-[N'-(acetyloxy)carbamimidoyl]phenyl acetate 
• 58599-05-6 3-(5-Methyl-[1,2,4]oxadiazol-3-yl)phenol 
• 1363593-66-1 8-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenoxy]-3,4-dihydro-2H-5,1,2-benzoxathiazepine 1,1-dioxide 
• 1363593-64-9 3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl acetate 
• 1363593-73-0 tert-butyl 8-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenoxy]-3,4-dihydro-2H-5,1,2-benzoxathiazepine-2-carboxylate 1,1-dioxide 
• 10185-82-7 3-(5-isobutyl-1,2,4-oxadiazol-3-yl)phenol 

Relevant articles and documents

Synergism of a novel 1,2,4-oxadiazole-containing derivative with oxacillin against methicillin-resistant staphylococcus aureus

Staphylococcus aureus is an important opportunistic pathogen that causes many infections in humans and animals. The inappropriate use of antibiotics has favored the diffusion of methicillin-resistant S. aureus (MRSA), nullifying the efforts undertaken in

3-Aryl-1,2,4-oxadiazole Derivatives Active Against Human Rhinovirus

The human rhinovirus (hRV) is the causative agent of the common cold that often aggravates respiratory complications in patients with asthma or chronic obstructive pulmonary disease. The high rate of mutations and variety of serotypes are limiting the development of anti-hRV drugs, which emphasizes the need for the discovery of novel lead compounds. Previously, we identified antiviral compound 1 that we used here as the starting material for developing a novel compound series with high efficacy against hRV-A and -B. Improved metabolic stability was achieved by substituting an ester moiety with a 1,2,4-oxadiazole group. Specifically, compound 3k exhibited a high efficacy against hRV-B14, hRV-A21, and hRV-A71, with EC50 values of 66.0, 22.0, and 3.7 nM, respectively, and a relevant hepatic stability (59.6 and 40.7% compound remaining after 30 min in rat and human liver microsomes, respectively). An in vivo study demonstrated that 3k possessed a desirable pharmacokinetic profile with low systemic clearance (0.158 L·h-1·kg-1) and modest oral bioavailability (27.8%). Hence, 3k appears to be an interesting candidate for the development of antiviral lead compounds.

PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS

The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases. Wherein R1, R2 and R3 are as defined in the description.